Intracellular boosting of human immunodeficiency virus (HIV) protease inhibitors

Completed

• Conditions: Human immunodeficiency virus (HIV) pharmacology; Unspecified human immunodeficiency virus [HIV] disease; Infections and Infestations

• Registration Number: ISRCTN76548641
• Lead Sponsor: Royal Liverpool and Broadgreen University Hospitals Trust (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2008-11-13
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 18

Inclusion Criteria

1. The ability to understand and sign a written informed consent form, prior to participation in any screening procedures and must be willing to comply with all study requirements
2. Male or female patients
3. Aged 18 years and above
4. HIV positive

Exclusion Criteria

1. History of drug sensitivity or drug allergy to lopinavir, ritonavir, furosemide or dipyridamole
2. Aged less than 18 years
3. Pregnant or lactating women
4. CD4 less than 100 x 10^6 L
5. Viral load greater than 5000 copies
6. Anaemia (haemoglobin [Hb] less than 10.0 g/dl)
7. Severe coronary artery disease
8. Unstable angina
9. Recent myocardial infarction or haemodynamic instability
10. Hypovolaemia or dehydration
11. Renal dysfunction (estimated glomerular filtration rate [eGFR] less than 70 ml/min/1.73 m^2)
12. Severe hypokalaemia (K+ less than 3.0 mmol/l)
13. Severe hyponatraemia (Na+ less than 130 mmol/l)
14. Men with symptomatic urinary outflow obstruction
15. Severe hypotension (systolic less than 100 mmHg or diastolic less than 60 mmHg)
16. Women of childbearing age unless using appropriate contraception
17. Any known bleeding disorders
18. International normalised ratio (INR) less than 1.5
19. Platelets less than 100 x 10^9

Study & Design

• Study Type: Interventional
• Study Design: Not specified